mProX™ Human CD93 Stable Cell Line

Product Information

Target Family

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1; CNE-2

Target Classification

CD Cell Lines

Gene ID

Human:22918

UniProt ID

Human:Q9NPY3

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

CD93 is a protein expressed by brain endothelial cells (BECs) and has potential applications in neurological and neurovascular conditions. It may serve as a sensitive plasma biomarker for cerebral small vessel disease and dementia risk. A study identified 28 BEC-enriched proteins in plasma, including CD93, which were associated with white matter lesion volumes, cerebral microhemorrhages, and lacunar infarcts. Another study focused on adenocarcinoma of the esophagogastric junction (AEG) and identified CD93 as a hub gene related to tumorigenesis. In chronic Leishmania infection, CD93 was found to be expressed in parasitized cells, including monocytes, macrophages, megakaryocytes, basophils, and natural killer cells. CD93 was also implicated in platelet activation and surface expression of the protease activated receptor 4 (PAR4). It supported platelet aggregation and stabilization of PAR4 on the cell surface. Additionally, CD93 and its natural ligands, IGFBP7 and MMRN2, were considered potential targets for antiangiogenic therapy in solid tumors. CD93 was found to play a role in angiogenesis and could be targeted to normalize tumor vasculature.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human CD93 Stable Cell Line (S01YF-1023-PY231). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Taylor Williams (Verified Customer)

What is the role of CD93 in inflammation and disease? Sep 14 2023

chat Patrick Liam (Creative Biolabs Scientific Support)

CD93 modulates angiogenesis, inflammation, and tumor growth, and its expression and function are significant in various pathologies, making it a potential therapeutic target. Sep 14 2023

chat Alex Brown (Verified Customer)

How does CD93 influence platelet activation? Jan 23 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

CD93 supports platelet activation triggered by protease-activated receptor 4 stimulation and is required for stabilizing the expression of thrombin receptors on cell surfaces. Jan 23 2022

Published Data

Fig.1 Knockdown of CD93 inhibited CNE2 cell proliferation

The expression of CD93 was analyzed through Western blot and immunofluorescence techniques subsequent to the CD93 knockdown in CNE2 cells. A significant difference at a significance level of *P < 0.05 was observed through a t-test. Furthermore, cell proliferation was assessed utilizing the CCK-8 assay, yielding a significance level of *P < 0.05.

Ref: Bao, Lili, et al. "Elevated expression of CD93 promotes angiogenesis and tumor growth in nasopharyngeal carcinoma." Biochemical and biophysical research communications 476.4 (2016): 467-474.

Pubmed: 27255994

DOI: 10.1016/j.bbrc.2016.05.146

Research Highlights

Cordon, Jenifer. et al. "Identification of Clinically Relevant Brain Endothelial Cell Biomarkers in Plasma." Stroke, 2023.
In their study, the researchers examined the potential of brain endothelial cell (BEC)-expressed proteins as plasma biomarkers for neurological and neurovascular disorders, such as cerebral small vessel disease. BECs represent the main cell population of the blood-brain barrier. The findings suggest that these proteins may serve as sensitive indicators for these conditions. These results could have implications for the diagnosis and management of neurological and neurovascular diseases, highlighting the importance of monitoring BEC-specific protein changes in plasma.
Cordon, Jenifer. et al. "Identification of Clinically Relevant Brain Endothelial Cell Biomarkers in Plasma." Stroke, 2023.
Pubmed: 37814955 DOI: 10.1161/STROKEAHA.123.043908

Lai, Zhiyong. et al. "Hub genes in adenocarcinoma of the esophagogastric junction based on weighted gene co-expression network analysis and immunohistochemistry." Translational oncology, 2023.
Gastric cancer (GC) is ranked as the fifth most prevalent malignant tumor, often resulting in fatal outcomes. A major type of GC, adenocarcinoma of the esophagogastric junction (AEG), accounts for approximately 50% of all GC cases. Despite ongoing research, the underlying mechanisms of AEG remain not well understood. To resolve this, this research sought to identify key genes using weighted gene co-expression networks and immunohistochemistry analyses.
Lai, Zhiyong. et al. "Hub genes in adenocarcinoma of the esophagogastric junction based on weighted gene co-expression network analysis and immunohistochemistry." Translational oncology, 2023.
Pubmed: 37689006 DOI: 10.1016/j.tranon.2023.101781